Groowe Groowe / Newsroom / GILD
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GILD News

Gilead Sciences Inc

Xilio Therapeutics Announces Pricing of Underwritten Offering

globenewswire.com
XLO GILD

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

businesswire.com
GILD

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

businesswire.com
GILD

$12 Bn Private LTE/5G Network Market Forecasts, 2025-2026 & 2030: Insights from 35 New Executive Interviews with Market Leading Companies

globenewswire.com
ERIC NOK MSFT AMZN SWKS AVGO QCOM INTC CSCO HPE SNPS AMAT LRCX KLAC ASML MU WDC SE NVDA AMD MRVL NXPI QRVO ON ADI TXN MCHP INFY IBM ORCL SAP ACN CTAS CDNS GLW AVNT ATOS NTES BABA JD PDD IQ BIDU HTHT BILI VIPS NIO LI XPEV RIVN LCID TSLA F GM STLA CHPT PLTR SNOW DDOG CRM NOW PANW FTNT ZS CRWD MDB PYPL COIN UPST SOFI AFRM HOOD ETSY GOOG HPQ DELL SMCI ALGN IDXX REGN VRTX GILD AMGN BMY PFE MRK JNJ ABBV LLY BIIB AZN SNY TEVA BMRN EXPE BKNG MAR H IHG WYNN LVS MGM CCL RCL NCLH AAL DAL UAL LUV BA GD LMT RTX HON CAT DE GE MMM ROK EMR ILMN MELI ADBE GOOGL AAPL T VZ TMUS CMCSA CHTR

Idiopathic Pulmonary Fibrosis Market Poised to Reach US$ 6,736.49 Million by 2035 as Late-Stage Pipelines and Novel Mechanisms Transform Treatment Outcomes | Astute Analytica

globenewswire.com
BIIB GILD UTHR

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica

globenewswire.com
JNJ AZN MRK ORCL IQV PFE NVS TAK BMY SNY LLY GILD ACN DLTR IBM

TAKIS® LAUNCHES SIX INTENSE NEW FLAVORS, UNLEASHING A FULL-FLAVOR TAKEOVER

prnewswire.com
GILD

Total Lab Automation Research Report 2026: Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2025-2031

globenewswire.com
TMO DHR ABT BIIB QGEN HOLX TECH HPE IBM MSFT GOOG AMZN NVDA AMD INTC ROK HON GE XRAY ETR BKR HAL SLB LMT GD BA RTX CAT DE MMM AVGO ADSK CSCO ACN ORCL SAP CRM NFLX DIS CMCSA VZ T PFE MRK JNJ BMY GILD AMGN REGN VRTX LRCX ASML MU WDC EXAS ILMN MDLZ KO PEP SBUX MCD NKE TGT WMT HD LOW COST MGM LVS WYNN MAR

FDA Approves Label Update for Kite’s Yescarta ® for Relapsed/Refractory Primary Central Nervous System Lymphoma

businesswire.com
GILD

Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies

globenewswire.com
UNH CVS GILD BMY